Nastaran Safdarian, MD
Allergy & Immunology · Dallas, TXNPI 1144414434
Payments from drug & device makers
Across 472 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$1K
- GSK$921
- Takeda Pharmaceuticals U.S.A., Inc.$850
- Sanofi$567
- Octapharma USA, Inc.$558
- plus $5K from 32 others
What the payments were for
- Consulting fees$270%
- Food & beverage$9,95398%
- Education$2232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 79 | $1,392 |
| Regeneron Healthcare Solutions, Inc. | 58 | $1,228 |
| GSK | 58 | $921 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $850 |
| Sanofi | 22 | $567 |
| Octapharma USA, Inc. | 15 | $558 |
| Grifols USA, LLC | 28 | $546 |
| Novo Nordisk | 4 | $526 |
| Novartis | 26 | $466 |
| Genentech USA, Inc. | 21 | $437 |
| Amgen | 14 | $333 |
| Biocryst US Sales Co., LLC | 16 | $291 |
| Alk-abello, Inc | 12 | $231 |
| LEO Pharma Inc. | 8 | $194 |
| Optinose US, Inc. | 11 | $194 |
| CSL Behring | 6 | $185 |
| Pharming Healthcare, Inc. | 8 | $175 |
| Sanofi-aventis U.S. LLC | 2 | $155 |
| Kaleo, Inc. | 6 | $134 |
| Pfizer | 6 | $125 |
| Teva Pharmaceuticals USA, Inc. | 6 | $114 |
| Blueprint Medicines Corporation | 4 | $75 |
| ADMA Biomanufacturing LLC | 3 | $74 |
| Azurity Pharmaceuticals, Inc. | 4 | $63 |
| Boehringer Ingelheim | 2 | $47 |
| Covis Pharma GmbH | 2 | $39 |
| Organon | 4 | $37 |
| Phadia US Inc. | 2 | $35 |
| Lilly USA, LLC | 1 | $26 |
| Greer Laboratories, Inc. | 1 | $26 |
| Kedrion Biopharma, Inc. | 1 | $24 |
| Insmed, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $22 |
| Merck | 1 | $20 |
| Hospira, Inc. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| GC Biopharma USA, Inc. | 1 | $18 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,203 in reported general payments places this provider in the 60th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $21,385 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $11,894 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,340 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $6,173 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $4,990 |
| Azelastine Hcl | 44 | $1,420 |
| Montelukast Sodium | 75 | $900 |
| Fluticasone Propionate | 35 | $715 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $564 |
| Ipratropium Bromide | 17 | $538 |
| Levocetirizine Dihydrochloride | 22 | $186 |
| Famotidine | 16 | $133 |
| Hydroxyzine Hcl | 11 | $122 |
| Azithromycin | 11 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $921 | $33,71553 claims |
| AstraZenecaBreztri Aerosphere | $1,392 | $11,89416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Dallas
- Barbara BaxterDallas$2.5M
- Richard WassermanDallas$1.9M
- Elliot GinchanskyDallas$477K
- Matthew FeldmanDallas$410K
- Lara GrossDallas$171K
- Anil NandaDallas$86K
- Sonak DaulatDallas$72K
- Joseph WestDallas$39K
- William HowlandAustin$3.6M
- Russell PerryBeaumont$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.